Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha-2b and Ribavirin) in Japanese Patients

A Phase 2a Study of BMS-790052 in Combination With Peginterferon Alfa-2b (PegIntron®) and Ribavirin (Rebetol®) in Japanese Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

The purpose of this study is to identify at least 1 dose of daclatasvir that is safe, well tolerated, and efficacious when combined with peginterferon-alfa and ribavirin for the treatment of hepatitis C virus genotype 1 in chronically infected patients who are treatment-naïve and nonresponsive to the standard of care

Key Inclusion Criteria:

• Patients chronically infected with hepatitis C virus (HCV) genotype 1
• HCV RNA viral load ≥10*5* IU/mL at screening
• Naïve or nonresponsive to the current standard of care

Key Exclusion Criteria:

• Cirrhosis
• Hepatocellular carcinoma
• Coinfection with hepatitis B virus, HIV-1 or HIV-2